Latest Update: Impact of current COVID-19 situation has been considered in this report while making the analysis.
Global Palonosetron Market by Type (Injection 0.25 mg/5 mL, Injection 20 mcg/kg (max 1.5 mg)), By Application (Adults, Children) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030-report

Global Palonosetron Market by Type (Injection 0.25 mg/5 mL, Injection 20 mcg/kg (max 1.5 mg)), By Application (Adults, Children) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030

Report ID: 130336 3300 Pharma & Healthcare 377 231 Pages 5 (48)
                                          

The global palonosetron market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The market is driven by factors such as increasing incidence of chemotherapy-induced nausea and vomiting (CINV) in adults and children, rising prevalence of cancer globally, and increasing number of cancer patients undergoing chemotherapy treatment. The injection 0.25 mg/5 mL segment accounted for the largest share in the global palonosetron market in 2018 owing to its high efficacy rate and low cost per dose. The injection 20 mcg/kg (max 1.5 mg) segment is expected to grow at a higher CAGR during the forecast period due to its high efficacy rate and low cost per dose compared with other dosage forms such as tablets or oral solution. North America accounted for the largest share in the global palonosetron market in 2018 due to increased awareness about CINV among healthcare professionals, rising prevalence of cancer cases, availability of reimbursement policies for antiemetics drugs by insurance companies, and presence of major players operating across this region such as Allergan plc., Merck & Co., Inc, Pfizer Inc, GlaxoSmithKline plc., Novartis AG, AstraZeneca PLC., Eli Lilly & Company Ltd, Teva Pharmaceutical Industries Ltd, Johnson & Johnson Services Incorporated among others. -Palonosetron is a 5HT3 receptor antagonist that is used to prevent nausea and vomiting caused by chemotherapy. -In 2013, it was the most prescribed antiemetic in the US with over 1 million prescriptions written.

Industry Growth Insights published a new data on “Palonosetron Market”. The research report is titled “Palonosetron Market research by Types (Injection 0.25 mg/5 mL, Injection 20 mcg/kg (max 1.5 mg)), By Applications (Adults, Children), By Players/Companies Helsinn Therapeutics, Teva, Dr. Reddys Laboratories, Cipla, Pfizer, Sandoz, Aurobindo, Sagent Pharmaceuticals, Fresenius Kabi, Qilu Pharmaceutical, Jiangsu Aosaikang Pharmaceutical, Sichuan Hairong Pharmaceutical, Exela Pharma”.

Scope Of The Report

Report Attributes

Report Details

Report Title

Palonosetron Market Research Report

By Type

Injection 0.25 mg/5 mL, Injection 20 mcg/kg (max 1.5 mg)

By Application

Adults, Children

By Companies

Helsinn Therapeutics, Teva, Dr. Reddys Laboratories, Cipla, Pfizer, Sandoz, Aurobindo, Sagent Pharmaceuticals, Fresenius Kabi, Qilu Pharmaceutical, Jiangsu Aosaikang Pharmaceutical, Sichuan Hairong Pharmaceutical, Exela Pharma

Regions Covered

North America, Europe, APAC, Latin America, MEA

Base Year

2021

Historical Year

2019 to 2020 (Data from 2010 can be provided as per availability)

Forecast Year

2030

Number of Pages

231

Number of Tables & Figures

162

Customization Available

Yes, the report can be customized as per your need.


Global Palonosetron Industry Outlook


Global Palonosetron Market Report Segments:

The global Palonosetron market is segmented on the basis of:

Types

Injection 0.25 mg/5 mL, Injection 20 mcg/kg (max 1.5 mg)

The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.

Applications

Adults, Children

The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.

Some of the companies that are profiled in this report are:

  1. Helsinn Therapeutics
  2. Teva
  3. Dr. Reddys Laboratories
  4. Cipla
  5. Pfizer
  6. Sandoz
  7. Aurobindo
  8. Sagent Pharmaceuticals
  9. Fresenius Kabi
  10. Qilu Pharmaceutical
  11. Jiangsu Aosaikang Pharmaceutical
  12. Sichuan Hairong Pharmaceutical
  13. Exela Pharma

Global Palonosetron Market Overview


Highlights of The Palonosetron Market Report:

  1. The market structure and projections for the coming years.
  2. Drivers, restraints, opportunities, and current trends of Alpha Hydroxy Acid for Cosmetic Market.
  3. Historical data and forecast.
  4. Estimations for the forecast period 2030.
  5. Developments and trends in the market.
  6. By Type:

    1. Injection 0.25 mg/5 mL
    2. Injection 20 mcg/kg (max 1.5 mg)
  1. By Application:

    1. Adults
    2. Children
  1. Market scenario by region, sub-region, and country.
  2. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
  3. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
  4. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Palonosetron Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.

Regional Analysis

  • North America
  • Europe
  • Asia Pacific
  • Middle East & Africa
  • Latin America

Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.

The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.

How you may use our products:

  • Correctly Positioning New Products
  • Market Entry Strategies
  • Business Expansion Strategies
  • Consumer Insights
  • Understanding Competition Scenario
  • Product & Brand Management
  • Channel & Customer Management
  • Identifying Appropriate Advertising Appeals

Global Palonosetron Market Statistics

8 Reasons to Buy This Report

  1. Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
  2. Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
  3. Implemented Robust Methodology to Prepare the Report
  4. Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
  5. Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
  6. Provides Information About the Top-winning Strategies Implemented by Industry Players.
  7. In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
  8. Customization of the Report Available
                                            
1. Executive Summary

2. Assumptions and Acronyms Used

3. Research Methodology

4. Palonosetron Market Overview
   4.1. Introduction
      4.1.1. Market Taxonomy
      4.1.2. Market Definition
   4.2. Macro-Economic Factors
      4.2.1. Industry Outlook
   4.3. Palonosetron Market Dynamics
      4.3.1. Market Drivers
      4.3.2. Market Restraints
      4.3.3. Opportunity
      4.3.4. Market Trends
   4.4. Palonosetron Market - Supply Chain
   4.5. Global Palonosetron Market Forecast
      4.5.1. Palonosetron Market Size (US$ Mn) and Y-o-Y Growth
      4.5.2. Palonosetron Market Size (000’ Units) and Y-o-Y Growth
      4.5.3. Palonosetron Market Absolute $ Opportunity

5. Global Palonosetron Market Analysis and Forecast by Type
   5.1. Market Trends
   5.2. Introduction
      5.2.1. Basis Point Share (BPS) Analysis by Type
      5.2.2. Y-o-Y Growth Projections by Type
   5.3. Palonosetron Market Size and Volume Forecast by Type
      5.3.1. Injection 0.25 mg/5 mL
      5.3.2. Injection 20 mcg/kg (max 1.5 mg)
   5.4. Absolute $ Opportunity Assessment by Type
   5.5. Market Attractiveness/Growth Potential Analysis by Type

6. Global Palonosetron Market Analysis and Forecast by Application
   6.1. Market Trends
   6.2. Introduction
      6.2.1. Basis Point Share (BPS) Analysis by Application
      6.2.2. Y-o-Y Growth Projections by Application
   6.3. Palonosetron Market Size and Volume Forecast by Application
      6.3.1. Adults
      6.3.2. Children
   6.4. Absolute $ Opportunity Assessment by Application
   6.5. Market Attractiveness/Growth Potential Analysis by Application

7. Global Palonosetron Market Analysis and Forecast by Sales Channel
   7.1. Market Trends
   7.2. Introduction
      7.2.1. Basis Point Share (BPS) Analysis by Sales Channel 
      7.2.2. Y-o-Y Growth Projections by Sales Channel
   7.3. Palonosetron Market Size and Volume Forecast by Sales Channel 
      7.3.1. Manufacturer/Distributor/Service Provider
      7.3.2. Aftermarket
   7.4. Absolute $ Opportunity Assessment by Sales Channel
   7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel

8. Global Palonosetron Market Analysis and Forecast by Region
   8.1. Market Trends
   8.2. Introduction
      8.2.1. Basis Point Share (BPS) Analysis by Region
      8.2.2. Y-o-Y Growth Projections by Region
   8.3. Palonosetron Market Size and Volume Forecast by Region
      8.3.1. North America
      8.3.2. Latin America
      8.3.3. Europe
      8.3.4. Asia Pacific
      8.3.5. Middle East and Africa (MEA)
   8.4. Absolute $ Opportunity Assessment by Region
   8.5. Market Attractiveness/Growth Potential Analysis by Region
   8.6. Global Palonosetron Demand Share Forecast, 2019-2029

9. North America Palonosetron Market Analysis and Forecast
   9.1. Introduction
      9.1.1. Basis Point Share (BPS) Analysis by Country
      9.1.2. Y-o-Y Growth Projections by Country
   9.2. North America Palonosetron Market Size and Volume Forecast by Country
      9.2.1. U.S.
      9.2.2. Canada
   9.3. Absolute $ Opportunity Assessment by Country
   9.4. North America Palonosetron Market Size and Volume Forecast by Application
      9.4.1. Adults
      9.4.2. Children
   9.5. Basis Point Share (BPS) Analysis by Application
   9.6. Y-o-Y Growth Projections by Application
   9.7. North America Palonosetron Market Size and Volume Forecast by Type
      9.7.1. Injection 0.25 mg/5 mL
      9.7.2. Injection 20 mcg/kg (max 1.5 mg)
   9.8. Basis Point Share (BPS) Analysis by Type
   9.9. Y-o-Y Growth Projections by Type
   9.10. Market Attractiveness/Growth Potential Analysis
      9.10.1. By Country
      9.10.2. By Product Type
      9.10.3. By Application
      9.10.4. By Sales Channel
   9.11. North America Palonosetron Demand Share Forecast, 2019-2029

10. Latin America Palonosetron Market Analysis and Forecast
   10.1. Introduction
      10.1.1. Basis Point Share (BPS) Analysis by Country
      10.1.2. Y-o-Y Growth Projections by Country
      10.1.3. Latin America Average Pricing Analysis
   10.2. Latin America Palonosetron Market Size and Volume Forecast by Country
      10.2.1. Brazil
      10.2.2. Mexico
      10.2.3. Rest of Latin America
   10.3. Absolute $ Opportunity Assessment by Country
   10.4. Latin America Palonosetron Market Size and Volume Forecast by Application
      10.4.1. Adults
      10.4.2. Children
   10.5. Basis Point Share (BPS) Analysis by Application
   10.6. Y-o-Y Growth Projections by Application
   10.7. Latin America Palonosetron Market Size and Volume Forecast by Type
      10.7.1. Injection 0.25 mg/5 mL
      10.7.2. Injection 20 mcg/kg (max 1.5 mg)
   10.8. Basis Point Share (BPS) Analysis by Type
   10.9. Y-o-Y Growth Projections by Type
   10.10. Market Attractiveness/Growth Potential Analysis
      10.10.1. By Country
      10.10.2. By Product Type
      10.10.3. By Application
      10.10.4. By Sales Channel
   10.11. Latin America Palonosetron Demand Share Forecast, 2019-2029

11. Europe Palonosetron Market Analysis and Forecast
   11.1. Introduction
      11.1.1. Basis Point Share (BPS) Analysis by Country
      11.1.2. Y-o-Y Growth Projections by Country
      11.1.3. Europe Average Pricing Analysis
   11.2. Europe Palonosetron Market Size and Volume Forecast by Country
      11.2.1. Germany
      11.2.2. France
      11.2.3. Italy
      11.2.4. U.K.
      11.2.5. Spain
      11.2.6. Russia
      11.2.7. Rest of Europe
   11.3. Absolute $ Opportunity Assessment by Country
   11.4. Europe Palonosetron Market Size and Volume Forecast by Application
      11.4.1. Adults
      11.4.2. Children
   11.5. Basis Point Share (BPS) Analysis by Application
   11.6. Y-o-Y Growth Projections by Application
   11.7. Europe Palonosetron Market Size and Volume Forecast by Type
      11.7.1. Injection 0.25 mg/5 mL
      11.7.2. Injection 20 mcg/kg (max 1.5 mg)
   11.8. Basis Point Share (BPS) Analysis by Type
   11.9. Y-o-Y Growth Projections by Type
   11.10. Market Attractiveness/Growth Potential Analysis
      11.10.1. By Country
      11.10.2. By Product Type
      11.10.3. By Application
      11.10.4. By Sales Channel
   11.11. Europe Palonosetron Demand Share, 2019-2029

12. Asia Pacific Palonosetron Market Analysis and Forecast
   12.1. Introduction
      12.1.1. Basis Point Share (BPS) Analysis by Country
      12.1.2. Y-o-Y Growth Projections by Country
      12.1.3. Asia Pacific Average Pricing Analysis
   12.2. Asia Pacific Palonosetron Market Size and Volume Forecast by Country
      12.2.1. China
      12.2.2. Japan
      12.2.3. South Korea
      12.2.4. India
      12.2.5. Australia
      12.2.6. Rest of Asia Pacific (APAC)
   12.3. Absolute $ Opportunity Assessment by Country
   12.4. Asia Pacific Palonosetron Market Size and Volume Forecast by Application
      12.4.1. Adults
      12.4.2. Children
   12.5. Basis Point Share (BPS) Analysis by Application
   12.6. Y-o-Y Growth Projections by Application
   12.7. Asia Pacific Palonosetron Market Size and Volume Forecast by Type
      12.7.1. Injection 0.25 mg/5 mL
      12.7.2. Injection 20 mcg/kg (max 1.5 mg)
   12.8. Basis Point Share (BPS) Analysis by Type
   12.9. Y-o-Y Growth Projections by Type
   12.10. Market Attractiveness/Growth Potential Analysis
      12.10.1. By Country
      12.10.2. By Product Type
      12.10.3. By Application
      12.10.4. By Sales Channel
   12.11. Asia Pacific Palonosetron Demand Share, 2019-2029

13. Middle East & Africa Palonosetron Market Analysis and Forecast
   13.1. Introduction
      13.1.1. Basis Point Share (BPS) Analysis by Country
      13.1.2. Y-o-Y Growth Projections by Country
      13.1.3. Asia Pacific Average Pricing Analysis
   13.2. Middle East & Africa Palonosetron Market Size and Volume Forecast by Country
      13.2.1. Saudi Arabia
      13.2.2. South Africa
      13.2.3. UAE
      13.2.4. Rest of Middle East & Africa (MEA)
   13.3. Absolute $ Opportunity Assessment by Country
   13.4. Middle East & Africa Palonosetron Market Size and Volume Forecast by Application
      13.4.1. Adults
      13.4.2. Children
   13.5. Basis Point Share (BPS) Analysis by Application
   13.6. Y-o-Y Growth Projections by Application
   13.7. Middle East & Africa Palonosetron Market Size and Volume Forecast by Type
      13.7.1. Injection 0.25 mg/5 mL
      13.7.2. Injection 20 mcg/kg (max 1.5 mg)
   13.8. Basis Point Share (BPS) Analysis by Type
   13.9. Y-o-Y Growth Projections by Type
   13.10. Market Attractiveness/Growth Potential Analysis
      13.10.1. By Country
      13.10.2. By Product Type
      13.10.3. By Application
      13.10.4. By Sales Channel
   13.11. Middle East & Africa Palonosetron Demand Share, 2019-2029

14. Competition Landscape
   14.1. Global Palonosetron Market: Market Share Analysis
   14.2. Palonosetron Distributors and Customers
   14.3. Palonosetron Market: Competitive Dashboard
   14.4. Company Profiles (Details – Overview, Financials, Developments, Strategy) 
      14.4.1. Helsinn Therapeutics
         14.4.1.1. Overview
         14.4.1.2. Financials
         14.4.1.3. Developments
         14.4.1.4. Strategic Outlook
      14.4.2. Teva
         14.4.2.1. Overview
         14.4.2.2. Financials
         14.4.2.3. Developments
         14.4.2.4. Strategic Outlook
      14.4.3. Dr. Reddys Laboratories
         14.4.3.1. Overview
         14.4.3.2. Financials
         14.4.3.3. Developments
         14.4.3.4. Strategic Outlook
      14.4.4. Cipla
         14.4.4.1. Overview
         14.4.4.2. Financials
         14.4.4.3. Developments
         14.4.4.4. Strategic Outlook
      14.4.5. Pfizer
         14.4.5.1. Overview
         14.4.5.2. Financials
         14.4.5.3. Developments
         14.4.5.4. Strategic Outlook
      14.4.6. Sandoz
         14.4.6.1. Overview
         14.4.6.2. Financials
         14.4.6.3. Developments
         14.4.6.4. Strategic Outlook
      14.4.7. Aurobindo
         14.4.7.1. Overview
         14.4.7.2. Financials
         14.4.7.3. Developments
         14.4.7.4. Strategic Outlook
      14.4.8. Sagent Pharmaceuticals
         14.4.8.1. Overview
         14.4.8.2. Financials
         14.4.8.3. Developments
         14.4.8.4. Strategic Outlook
      14.4.9. Fresenius Kabi
         14.4.9.1. Overview
         14.4.9.2. Financials
         14.4.9.3. Developments
         14.4.9.4. Strategic Outlook
      14.4.10. Qilu Pharmaceutical
         14.4.10.1. Overview
         14.4.10.2. Financials
         14.4.10.3. Developments
         14.4.10.4. Strategic Outlook
      14.4.11. Jiangsu Aosaikang Pharmaceutical
         14.4.11.1. Overview
         14.4.11.2. Financials
         14.4.11.3. Developments
         14.4.11.4. Strategic Outlook
      14.4.12. Sichuan Hairong Pharmaceutical
         14.4.12.1. Overview
         14.4.12.2. Financials
         14.4.12.3. Developments
         14.4.12.4. Strategic Outlook
      14.4.13. Exela Pharma
         14.4.13.1. Overview
         14.4.13.2. Financials
         14.4.13.3. Developments
         14.4.13.4. Strategic Outlook
      14.4.14. COMPANY 14
         14.4.14.1. Overview
         14.4.14.2. Financials
         14.4.14.3. Developments
         14.4.14.4. Strategic Outlook
      14.4.15. COMPANY 15
         14.4.15.1. Overview
         14.4.15.2. Financials
         14.4.15.3. Developments
         14.4.15.4. Strategic Outlook
      14.4.16. COMPANY 16
         14.4.16.1. Overview
         14.4.16.2. Financials
         14.4.16.3. Developments
         14.4.16.4. Strategic Outlook
      14.4.17. COMPANY 17
         14.4.17.1. Overview
         14.4.17.2. Financials
         14.4.17.3. Developments
         14.4.17.4. Strategic Outlook
      14.4.18. COMPANY 18
         14.4.18.1. Overview
         14.4.18.2. Financials
         14.4.18.3. Developments
         14.4.18.4. Strategic Outlook
      14.4.19. COMPANY 19
         14.4.19.1. Overview
         14.4.19.2. Financials
         14.4.19.3. Developments
         14.4.19.4. Strategic Outlook
      14.4.20. COMPANY 20
         14.4.20.1. Overview
         14.4.20.2. Financials
         14.4.20.3. Developments
         14.4.20.4. Strategic Outlook

Our Trusted Clients

Contact Us